Investigation to detect a possible sensitizing effect of Scheriproct or of the active ingredients contained therein has not been carried out. According to relevant data gained from spontaneous reports as well as contained in the literature, it is possible that not only individual ingredients of the formulation base but also the active ingredients themselves are responsible for the allergenic skin reactions which were observed only sporadically after the use of Scheriproct. There is, however, no risk of a sensitizing effect occurring other than in sporadic cases.
The drug's most common side effects are poor or reduced appetite, vomiting, lack of energy, diarrhea, and weakness. Occasionally, more serious side effects, including bloody diarrhea, collapse, severe sodium/potassium imbalance, and destruction of the adrenal gland may occur, and may result in death. In 2014, with input from CVM, the manufacturer updated the information about patient monitoring and side effects on the package insert. Although not proven to be caused by Vetoryl, some additional side effects reported to CVM and now included on the package insert are adrenal insufficiency, shaking, elevated liver enzymes and elevated kidney tests.